REGN240913C700000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment
Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
Express News | Dupixent® (Dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Express News | Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Sanofi Reports Positive Phase 3 Results for Dupixent for CSU
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,183
Regeneron Pharmaceuticals Announced New Analyses Of Eylea HD (Aflibercept) Injection 8 Mg And Eylea Injection 2 Mg Will Be Presented At The Annual Meeting Of The European Society Of Retina Specialists
Regeneron, Sanofi's Dupixent Drug Meets Main Goal in 2 Late-Stage Trials
Sanofi's Dupixent Drug Achieves Improvement for Skin Diseases
Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Express News | Dupixent® (Dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients With Chronic Spontaneous Urticaria (Csu)
Express News | Sanofi - Study Will Support Regulatory Submissions Around World, Starting With U.S. Later This Year
Dupixent (Dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
Dupixent (Dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients With Chronic Spontaneous Urticaria (CSU)
EYLEA HD (Aflibercept) Injection 8 Mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today